Previous 10 | Next 10 |
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizuma...
LA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters will be presented at VIRTUAL IMMUNOLOGY TM , the 2021 ...
Gainers: [[ELOX]] +19.9%. [[SURF]] +15.0%. [[EVK]] +14.3%. [[EQ]] +10.4%. [[HYFM]] +9.2%.Losers: [[EDAP]] -7.4%. [[IMVT]] -5.3%. [[BYND]] -4.8%. [[CRMD]] -4.8%. [[OSMT]] -3.7%. For further details see: ELOX, SURF, EDAP and IMVT among after-hours movers
Equillium (EQ) today released phase 1 data showing that its systemic lupus erythematosus candidate itolizumab was safe and tolerated.Itolizumab demonstrated a dose-dependent reduction of cell surface CD6 expression on effector T cells, a leading indicator of drug activity, consistent with its...
Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus Dose-dependent changes in pharmacodynamic markers observed with subcutaneous dosing were consistent with intravenous dosing of itolizumab LA JOLLA, Calif., March ...
Equillium (EQ): Q4 GAAP EPS of -$0.36 beats by $0.02.Cash, cash equivalents and short-term investments of $82.2M.Press Release For further details see: Equillium EPS beats by $0.02
Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021 LA JOLLA, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology comp...
Today, we take our first look at Equillium, a small development concern targeting acute graft-versus-host disease. The company has seen a lot of positive analyst commentary recently after it ditched its Covid19 efforts. A full analysis follows in the paragraphs below. For fu...
Full data from Equillium's (EQ) phase 1b/2 trial of itolizumab as a potential first-line treatment for acute graft-versus-host disease (aGVHD) provided further evidence that the mAb provided a complete response in a majority of patients in 15 days.Also, there was a clinically meaningful ...
EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid use Translational data demonstrates itolizumab’s impact on T cell effector ...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...